欢迎您访问中乔新舟官网!400-038-9959我的购物车(0)
您当前的位置:首页 > 产品中心
BC-3 人B淋巴细胞
英文名:BC-3
货号:ZQ0583
价格:¥1800.00
加入购物车,提交订单信息之后,我们会第一时间与您取得联系!
推荐组合

BC-3 人B淋巴细胞

¥1800.00
+

BC-3 人B淋巴细胞专用培养基

¥350.00 ¥480.00

配套完培,省时省力,单买细胞无优惠

=

细胞套餐惊爆价

¥2150 ¥2680.00
加入购物车
  • 产品说明
  • 产品规格
  • 参考文献
  • STR鉴定

产品名称

BC-3 人B淋巴细胞

货号

ZQ0583

产品介绍

BC-3是一种B淋巴细胞系,它源自于1995年从一名85岁白人男性患者的胸腔积液中分离得到的原发性渗出性(基于体腔的)淋巴瘤(PEL)。这种细胞系对于免疫学研究具有重要的价值,尤其是在研究Kaposi's sarcoma-associated herpesvirus(KSHV,也称为HHV-8)方面,因为BC-3细胞系含有KSHV的病毒基因组,但并不含有HIV或Epstein-Barr病毒(EBV)。此外,BC-3细胞也不含有其他常见的病毒,如单纯疱疹病毒1型和2型(HSV-1和HSV-2)以及巨细胞病毒(CMV)。
BC-3细胞系在科研中的应用包括研究淋巴瘤的发病机制、KSHV的复制和潜伏感染的激活,以及开发新的治疗方法。由于BC-3细胞不表达B细胞或T细胞的特异性抗原,但表达活化抗原,这使得它们成为研究淋巴瘤和相关免疫反应的重要模型。 

种属

性别/年龄

男性/85岁 

组织

胸腔积液

疾病

淋巴瘤 

细胞类型

肿瘤细胞:b淋巴细胞

形态学

成淋巴细胞

生长方式

悬浮

倍增时间

大约50~60小时 

培养基和添加剂

DMEM (中乔新舟  货号:ZQ-100)+10%胎牛血清(中乔新舟  货号:ZQ500-A)+1%P/S(中乔新舟  货号:CSP006

推荐完全培养基货号

ZM0583

生物安全等级

BSL-2

STR位点信息

Amelogenin:X
CSF1PO: 11,12
D2S1338:24,25
D3S1358:15,17
D5S818: 11,12
D7S820: 10,12
D8S1179:14,16
D13S317:11
D16S539:12
D18S51: 14,21.2
D19S433:14,15
D21S11: 29,30
FGA:18,22
Penta D: 8,13
Penta E: 7,15
TH01:6,9
TPOX:8,11
vWA:14,18 

培养条件

95%空气,5%二氧化碳;37℃

抗原表达/受体表达

*** 

基因表达

*** 

保藏机构

ATCC; CRL-3615

供应限制

仅供科研使用

货号

ZQ0583

发货规格

活细胞:T25培养瓶*1瓶或者1ml 冻存管*1支(细胞量约为5 x 10^5 cells/vial)二选一

发货形式

活细胞:常温运输;冻存管:干冰运输

储存温度

活细胞:培养箱;冻存管:液氮罐

产地

中国

供应限制

仅供科研使用


PubMed=8839859; DOI=10.1182/blood.V88.7.2648.bloodjournal8872648
Arvanitakis L., Mesri E.A., Nador R.G., Said J.W., Asch A.S., Knowles D.M., Cesarman E.
Establishment and characterization of a primary effusion (body cavity-based) lymphoma cell line (BC-3) harboring Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in the absence of Epstein-Barr virus.
Blood 88:2648-2654(1996)


PubMed=9766492; DOI=10.1038/sj.leu.2401160
Drexler H.G., Uphoff C.C., Gaidano G., Carbone A.
Lymphoma cell lines: in vitro models for the study of HHV-8+ primary effusion lymphomas (body cavity-based lymphomas).
Leukemia 12:1507-1517(1998)


Patent=US5908773
Cesarman E., Arvanitakis L., Knowles D.M., Mesri E.A.
KSHV positive cell lines.
Patent number US5908773, 01-Jun-1999


DOI=10.1016/B978-0-12-221970-2.50457-5
Drexler H.G.
The leukemia-lymphoma cell line factsbook.
(In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001)


PubMed=15613351; DOI=10.1128/JVI.79.2.1244-1251.2005; PMCID=PMC538532
Fan W., Bubman D., Chadburn A., Harrington W.J. Jr., Cesarman E., Knowles D.M.
Distinct subsets of primary effusion lymphoma can be identified based on their cellular gene expression profile and viral association.
J. Virol. 79:1244-1251(2005)


PubMed=17121789; DOI=10.1128/JVI.01757-06; PMCID=PMC1797584
Burd C.E., Sin S.-H., Dittmer D.P.
Functional p53 signaling in Kaposi's sarcoma-associated herpesvirus lymphomas: implications for therapy.
J. Virol. 81:1912-1922(2007)


PubMed=19608668; DOI=10.3324/haematol.2009.007260; PMCID=PMC2719041
Boulanger E., Marchio A., Hong S.-S., Pineau P.
Mutational analysis of TP53, PTEN, PIK3CA and CTNNB1/beta-catenin genes in human herpesvirus 8-associated primary effusion lymphoma.
Haematologica 94:1170-1174(2009)


PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113
Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)


PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)


PubMed=21685375; DOI=10.1182/blood-2010-12-323659; PMCID=PMC3158728
Roy D., Sin S.-H., Damania B., Dittmer D.P.
Tumor suppressor genes FHIT and WWOX are deleted in primary effusion lymphoma (PEL) cell lines.
Blood 118:e32-e39(2011)


PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)


PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)


PubMed=31160637; DOI=10.1038/s41598-019-44491-x; PMCID=PMC6547646
Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M., MacLeod R.A.F., Nagel S., Steube K.G., Uphoff C.C., Drexler H.G.
The LL-100 panel: 100 cell lines for blood cancer studies.
Sci. Rep. 9:8218-8218(2019)


PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

公司简介 / Company profile
上海中乔新舟生物科技有限公司
Shanghai Zhong Qiao Xin Zhou Biotechnology Co.,Ltd.
           上海中乔新舟生物科技有限公司(官网:www.zqxzbio.com)成立于2011年,历经...
联系我们 / Contact
电 话:021-56760357;021-56760351
传 真:
邮 箱:sales@zqxzbio.com
邮 编:200439
地 址:上海市宝山区长江南路180号
Copyright © 2014 ZQXZBIO All rights reserved.
技术支持:中乔新舟沪ICP备14008091号